Tetraphase Pharmaceuticals (NASDAQ:TTPH) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), Morningstar.com reports. The business had revenue of $1.15 million for the quarter, compared to analyst estimates of $2.09 million. Tetraphase Pharmaceuticals had a negative return on equity of 67.34% and a negative net margin of 421.64%.
TTPH stock traded down $0.08 during trading on Friday, reaching $2.17. 808,354 shares of the stock were exchanged, compared to its average volume of 1,007,372. Tetraphase Pharmaceuticals has a 1 year low of $2.01 and a 1 year high of $6.97. The company has a market capitalization of $117.35 million, a PE ratio of -0.83 and a beta of 2.67.
A number of hedge funds have recently modified their holdings of TTPH. Flagship Harbor Advisors LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $104,000. Cubist Systematic Strategies LLC raised its stake in Tetraphase Pharmaceuticals by 232.1% during the second quarter. Cubist Systematic Strategies LLC now owns 35,537 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 24,837 shares during the period. Canada Pension Plan Investment Board purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $179,000. Royce & Associates LP purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth about $556,000. Finally, Schwab Charles Investment Management Inc. raised its stake in Tetraphase Pharmaceuticals by 9.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 275,630 shares of the biopharmaceutical company’s stock worth $984,000 after purchasing an additional 23,337 shares during the period. 41.02% of the stock is currently owned by institutional investors.
A number of equities analysts recently weighed in on TTPH shares. HC Wainwright restated a “buy” rating on shares of Tetraphase Pharmaceuticals in a research report on Monday, July 16th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.25 price target on the stock in a research report on Thursday, August 2nd. Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Friday, August 3rd. Finally, B. Riley boosted their price target on shares of Tetraphase Pharmaceuticals from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, August 28th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $6.16.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/10/tetraphase-pharmaceuticals-ttph-announces-earnings-results-misses-estimates-by-0-02-eps.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
See Also: What is Cost of Debt?
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.